(Q46473134)

22 December 2017

title

A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes (English)

1 reference

22 December 2017

0 references

1 reference

Carine Beysen

1

1 reference

22 December 2017

Elizabeth J Murphy

2

1 reference

22 December 2017

Hirisadarahally Nagaraja

3

1 reference

22 December 2017

Martin Decaris

4

1 reference

22 December 2017

Timothy Riiff

5

1 reference

22 December 2017

Alex Fong

6

1 reference

22 December 2017

Marc K Hellerstein

7

1 reference

22 December 2017

Patrick J Boyle

8

1 reference

22 December 2017

publication date

18 July 2008

1 reference

22 December 2017

Journal of Lipid Research

published in

1 reference

22 December 2017

volume

49

1 reference

22 December 2017

issue

12

1 reference

22 December 2017

page(s)

2657-2663

1 reference

22 December 2017

Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans

cites work

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

De novo lipogenesis in humans: metabolic and regulatory aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Extracellular fatty acids are not utilized directly for the synthesis of very-low-density lipoprotein in primary cultures of rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

The effect of pioglitazone on the liver: role of adiponectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M800165-JLR200

10.1194/JLR.M800165-JLR200

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017